Related Experiment Videos

[The multidrug tumor cell resistance phenotype caused by the impaired cell death program]

D Iu Blokhin

    Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
    |February 1, 2005
    PubMed

    Insights

    Cancer therapy relies on inducing tumor cell death (apoptosis). Impaired apoptosis contributes to multidrug and radiation resistance in cancer progression.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Background:

    • Cancer cytoreductive therapy aims to reduce tumor mass by inducing cancer cell death.
    • Apoptosis, or programmed cell death, is a critical mechanism targeted by cancer treatments.
    • Dysregulation of cell death pathways is implicated in therapeutic resistance and tumor progression.

    Purpose of the Study:

    • To elucidate the role of tumor cell apoptosis induction in cancer cytoreductive therapy.
    • To investigate the significance of impaired apoptosis in the development of multidrug and radiation resistance.
    • To understand the contribution of defective cell death programs to tumor progression and treatment failure.

    Main Methods:

    • Review of existing literature on apoptosis induction in cancer therapy.
    • Analysis of molecular mechanisms underlying impaired cell death pathways.
    • Correlation of apoptosis defects with clinical outcomes in multidrug and radiation resistance.

    Main Results:

    • Tumor cell apoptosis induction is a key mechanism in effective cancer cytoreductive therapy.
    • Impaired apoptosis programs are significantly associated with the development of multidrug and radiation resistance.
    • Defective cell death pathways contribute to both natural tumor progression and acquired resistance phenotypes.

    Conclusions:

    • Targeting and restoring apoptosis induction is crucial for overcoming therapeutic resistance in cancer.
    • Understanding apoptosis dysregulation is vital for developing novel and effective anticancer strategies.
    • The integrity of the cell death program is a significant factor in cancer treatment success and patient prognosis.

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    Overview of Cell Death01:30

    Overview of Cell Death

    Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
    Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...